A dose scaling antivenin protocol in treatment of Daboia palaestinae envenomation may reduce morbidity and costs.

ABSTRACT:

Background

Daboia palaestinae is a leading cause of snakebite envenomation in the eastern Mediterranean, with substantial mortality in the absence of antivenin. Current recommended antivenin dose is 50 ml; however, antivenin is costly, may be difficult to obtain and is associated with substantial side effects. Thus, this study was designed to define the minimal effective antivenin dose and identify patients who can be safely managed without antivenin.

Methods

This retrospective single-center study was conducted in adults with suspected or confirmed D. palaestinae envenomation. Patients were treated via our previously developed envenomation protocol: no antivenin use for local symptoms and dose scaling for mild or severe systemic symptoms - initially 10 ml antivenin, with rep

SUBMITTER: Jakobson DJ 

PROVIDER: S-EPMC12200713 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature